J. F. Kurtzke: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). In: Neurology. Band33, Nr.11, 1. November 1983, ISSN0028-3878, S.1444–1444, doi:10.1212/WNL.33.11.1444 (neurology.org [abgerufen am 4. Februar 2021]).
S. Madeh Piryonesi, Sorour Rostampour, S. Abdurrahman Piryonesi: Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms. In: Multiple Sclerosis and Related Disorders. Band49, Nr.4, 1. Januar 2021, S.102740, doi:10.1016/j.msard.2021.102740 (elsevier.com [abgerufen am 2. Februar 2021]).
Caspar E. P. van Munster, Bernard M. J. Uitdehaag: Outcome Measures in Clinical Trials for Multiple Sclerosis. In: CNS Drugs. Band31, Nr.3, März 2017, ISSN1172-7047, S.217–236, doi:10.1007/s40263-017-0412-5, PMID 28185158.
elsevier.com
linkinghub.elsevier.com
S. Madeh Piryonesi, Sorour Rostampour, S. Abdurrahman Piryonesi: Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms. In: Multiple Sclerosis and Related Disorders. Band49, Nr.4, 1. Januar 2021, S.102740, doi:10.1016/j.msard.2021.102740 (elsevier.com [abgerufen am 2. Februar 2021]).
neurology.org
J. F. Kurtzke: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). In: Neurology. Band33, Nr.11, 1. November 1983, ISSN0028-3878, S.1444–1444, doi:10.1212/WNL.33.11.1444 (neurology.org [abgerufen am 4. Februar 2021]).
nih.gov
ncbi.nlm.nih.gov
Caspar E. P. van Munster, Bernard M. J. Uitdehaag: Outcome Measures in Clinical Trials for Multiple Sclerosis. In: CNS Drugs. Band31, Nr.3, März 2017, ISSN1172-7047, S.217–236, doi:10.1007/s40263-017-0412-5, PMID 28185158.
zdb-katalog.de
J. F. Kurtzke: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). In: Neurology. Band33, Nr.11, 1. November 1983, ISSN0028-3878, S.1444–1444, doi:10.1212/WNL.33.11.1444 (neurology.org [abgerufen am 4. Februar 2021]).
Caspar E. P. van Munster, Bernard M. J. Uitdehaag: Outcome Measures in Clinical Trials for Multiple Sclerosis. In: CNS Drugs. Band31, Nr.3, März 2017, ISSN1172-7047, S.217–236, doi:10.1007/s40263-017-0412-5, PMID 28185158.